Kinaxo Biotechnologies has formed a partnership with Biocatalyst International and Biofocus DPI to support the introduction of its cellular target profiling service to the US and Japanese market.
The Kinaxo cellular target profiling service enables drug developers to determine the native cellular protein interactions of small-molecule compounds in a physiological setting.
This provides significant benefits to any drug development programme, since knowledge of the compound's proteome-wide on- or off-target activities supports the prediction of its performance in clinical trials.
Biocatalyst International, based in New York, maintains a team of experienced PhD scientist and business development associates to communicate and support all the high-value aspects of Kinaxo's cellular target profiling service.
This will allow Kinaxo to serve its US customers with direct, local support.
In Japan, Kinaxo has partnered with Biofocus DPI, based in the UK, which will help Kinaxo establish a wide presence in Japan through its broad network of pharmaceutical relationships and intimate knowledge of the Japanese market.
